NEW YORK (GenomeWeb) – Molecular diagnostics firm Nucleix continues to advance its menu of epigenetic tests for cancer.
The Israeli firm recently announced the results of a multicenter study of its Bladder EpiCheck test in addition to netting €2.5 million ($2.9 million) in EU funding to develop a lung cancer assay.
Get the full story with
GenomeWeb Premium Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Be the first to comment